Section Arrow
PSTV.NASDAQ
- Plus Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/06/04 21:14 EDT
Last
 0.3527
-0.0262 (-6.91%)
Day High 
0.377099 
Prev. Close
0.3789 
1-M High
0.7458 
Volume 
4.60M 
Bid
0.3452
Ask
0.352
Day Low
0.342 
Open
0.3425 
1-M Low
0.26 
Market Cap 
6.44M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.32 
20-SMA 0.43 
50-SMA 0.69 
52-W High 2.6702 
52-W Low 0.24 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.34/-0.63
Enterprise Value
6.47M
Balance Sheet
Book Value Per Share
-1.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CLRBCellectar Biosciences0.4617+0.1841+66.32%-- 
NCNANuCana plc0.0461-0.0137-22.91%-- 
RXRXRecursion Pharmaceuticals4.91+0.52+11.85%-- 
HOTHHoth Therapeutics1.53+0.6102+66.34%-- 
SGMTSagimet Biosciences4.08+0.45+12.40%-- 
Quotes are at least 15-min delayed:2025/06/04 21:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.